Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Pathology and Cancer Research 2018

About Conference


The 15th International CME Congress on Pathology & Cancer Research is to be held at Vancouver, Canada during June 25-26, 2018 hosted by Conferences Series LLC. This conference could be an exceptional event that brings along a novel and International mixture of giant and medium pathology analysis, leading universities and Cancer Research analysis establishments creating the conference an ideal platform to share expertise in Pathology, Cancer Research and related fields.

Pathology is a major field in modern medical practice and diagnosis. The global digital pathology market, valued at $1.98 billion in 2012, is estimated to reach $5.7 billion by 2020. The In vitro diagnostics market revenue is expected to reach $74.65 billion by 2020, from the market value of $53.32 billion in 2013, at a CAGR of 5.34% during 2014-2020. Diagnostic Medicine has $35 billion market, growth 5-7% yearly. Pathology labs will take approximately $15-16 billion in revenue, and they will spend roughly 12% of their revenues with their suppliers all over USA.

Cancer research ranges from epidemiology, molecular bioscience to the performance of clinical trials to evaluate and compare applications of the various cancer treatments. These applications include surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy.

Who Should Attend?

Pathologists, Cancer Researchers, Oncologists, Cancer Pharmacologists, Cancer Therapists, Clinical Pathologists, Surgical Pathologists, pathologist in training and other healthcare professionals interested in the latest advances and techniques in the field. Another segment of target audience is Pharmaceutical researchers, Clinical organizations, Educational institutes. Anatomical Pathologists, Forensic Pathologists etc.,

The 15th International CME Congress on Pathology & Cancer Research will exhibit the products and services from commercial and non-commercial organizations like Pathology Lab Equipment manufacturers, Cell Diagnostics laboratories, Clinical Trial Sites, Business delegates and Equipment Manufacturers.

Why to attend Pathology and Cancer Research 2018?

  •  Best platform to develop new partnership & collaborations.
  •  Best location to speed up your route into every territory in the World.
  •  89% our conference attendees are the Key contact in their labs purchasing decisions.
  •  Our exhibitor booths were visited 4-5 times by 80% of the attendees during the conference.
  •  Past exhibitor’s feedback reveals ample of enquiries perceived from the conference attendees.
  •  Network development with both Academia and Business.

 

Pathology and Cancer Research 2018 is going to be held at Vancouver, Canada during June 25-26, 2018. The conference is organized with the theme "Shaping the Future for the Betterment of Human Health" which comprised of 22 sessions/tracks designed to offer comprehensive sessions that address current issues in this field.

Pathology is a branch of medical science primarily concerning the examination of organs, tissues, and bodily fluids in order to make a diagnosis of disease. Pathology is a major field in modern medical practice and health care. Pathology outlines the disease condition and treatment by using different pathology laboratory techniques. Pathology is used in the diagnosis, treatment and management of an increasing range of clinical conditions. Pathology investigations are an integral part of the clinical consultation and procedural process with overseas studies indicating that 70-80 per cent of all health care decisions affecting diagnosis or treatment involve a pathology investigation. 40% of pathology testing is used for diagnostic purposes, 40% for monitoring and 20% for preventative purposes.

The dominance of the North American market can be attributed to the favorable reimbursement scenario in the U.S. and the use of digital pathology to improve the quality of cancer diagnosis in Canada.

Theme: Shaping the Future for the Betterment of Human Health

Sessions

Track 1: OncoGenomics

Oncogenomics is a sub-field of genomics that characterizes cancer-associated genes. It focuses on genomic, epigenomic and transcript alterations in cancer. Comparative oncogenomics uses cross-species comparisons to identify oncogenes. Synthetic lethality arises when a combination of deficiencies in the expression of two or more genes leads to cell death, whereas a deficiency in only one of these genes does not. The deficiencies can arise through mutations, epigenetic alterations or inhibitors of one of the genes.

Track 2: Molecular Pathology

Molecular pathology is an emerging discipline within pathology which is concentrated in the study and conclusion of ailment through the examination of molecules within organs, tissues or bodily fluids. Molecular pathology imparts a few parts of practice with drug development, disease management strategies and is sometimes considered a crossover discipline. It is multi-disciplinary in nature and concentrates primarily on the sub-minute parts of diseases. A key consideration is that more accurate diagnosis is possible when the diagnosis is based on both the morphologic changes in tissues and on molecular testing of diseases like cancer. In this sub topics Molecular pathology is very useful in drug development and cancer. There are 5 associations and societies and the main association for Molecular Pathology is the Association of Molecular Pathology in USA. 78 universities are working on Molecular Pathology. Companies and hospitals around USA are associated with pathology. NIH has released $197,088 for Molecular Pathology research

Track 3: Cancer Biomarkers

Cancer biomarkers, particular those associated with genetic mutations or epigenetic alterations, often offer a quantitative way to determine when individuals are predisposed to particular types of cancers. A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. 

Track 4: Surgical Pathology

Surgical pathology is the investigation of tissues expelled from living patients amid surgery to help analyze a malady and focus a treatment arrangement. Regularly, the surgical pathologist gives consultation benefits in a wide assortment of organ indications and subspecialties. Surgical pathologists give symptomatic data and/or second conclusions. Case in point, when performing breast cancer surgery, a surgical pathologist's examination of tissues separated during the surgery can help the specialist to figure out if to evacuate lymph nodes under the arm, also. Surgical pathology incorporates both the physical examination of the tissue with the bare eye, and inspecting handled tissue under a magnifying instrument. There are 92 universities all over the USA where pathology research works are carried out in that main universities engaged in Surgical Pathology research are Stanford university of Medicine, John Hopkins University, Duke University and Washington University. National institute of cancer have released $ 1,265,135 for Surgical Pathology research.

Track 5: Cancer Diagnostics

Cancer Diagnostics plays an important role throughout your cancer treatment. Physical Examination, Laboratory tests, Biopsy, Imaging tests, Nuclear medicine scans, Endoscopy, Genetic tests are some of the diagnostic tests which are being carried out in the present world. Cancer Diagnostic testing involves tests and procedures to confirm the presence of disease and identify the correct tumor type, location, extent and stage. 

Track 6: Breast Pathology

Breast cancers can be divided into two main overarching groups: the carcinomas and the sarcomas. Carcinomas are cancers that arise from the epithelial component of the breast. The epithelial component consists of the cells that line the lobules and terminal ducts; under normal conditions, these epithelial cells are responsible for making milk. Carcinomas comprise the vast majority of all breast cancers, and will be further discussed below. Sarcomas are rare cancers that arise from the stromal (connective tissue) components of the breast. These stromal component cells include myofibroblasts and blood vessel cells, and cancers arising from these "supportive" cells include phyllodes tumors and angiosarcoma. Sarcomas account for less than 1% of primary breast cancers.

Track 7: Cancer Immunology

Cancer immune surveillance is considered to be an important host protection process to inhibit carcinogenesis and to maintain cellular homeostasis. Cancer immunology is a branch of immunology that studies interactions between the immune system and cancer cells.

Track 8: Cytopathology and Histopathology

Cytopathology is a diagnostic technique that examines cells from various body sites to determine the cause or the nature of disease. The first cytopathology test developed was the Pap test which has been widely utilized in the last 50 years for screening and diagnosing of cervical cancer and its precursors. The Pap test is considered the most successful screening test in medical history. Histopathology is the study of tissues (histology) and cells (cytology) and usually includes morbid anatomy (autopsies). Many refer to this specialty as Cellular Pathology. Histopathologists need good attention to detail for examining tissue and diagnosing disease. Histopathology involves the examination of sampled whole tissues under the microscope.

Track 9: Metastatic Carcinoma

Metastasis is the leading reason for the resultant mortality of patients with cancer. Once tumor cells acquire the ability to penetrate the surrounding tissues, the process of invasion is instigated as these motile cells pass through the basement membrane and extracellular matrix, progressing to intravasation as they penetrate the lymphatic or vascular circulation. Metastasis is the spread of cancer cells to new areas of the body often by way of the lymph system or bloodstream. Transcoelomic, Lymphatic spread, Hematogenous spread, transplantation or implantation are the different routes of cancer metastasis.

Track 10: Clinical Pathology

Clinical Pathology is a medical specialty that is concerned with the diagnosis of disease based on the laboratory analysis of bodily fluids. Clinical Pathology is one of the major classifications of Pathology. Clinical Pathology is accomplished through practical diagnosis of disease based on the laboratory analysis. Clinical Pathology is also useful in diagnosis of recent out broken diseases like Zika fever which is caused by zika virus. Zika virus is transmitted to people primarily through the bite of an infected Aedes species mosquito. Clinical Pathology so far covers the diagnostic testing, Implications of cancer patients, Prognostic value, clinical and non-clinical toxicology testing, Clinical finding of cancer and other disease. It emerges other subtopic like Neuropathology. The following topics are the latest research going on in clinical Pathology. There are 36 associations and societies all over the world and 90 universities are working for clinical pathology. Companies/Laboratories like Clinical Pathology Laboratories and other diagnostics laboratories are leading in research of this clinical pathology and 3400 hospitals around USA are associated with pathology. 

Track 11: Cancer Therapeutics

Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy) and synthetic lethality. Complete removal of the cancer without damage to the rest of the body (that is, achieving cure with near-zero adverse effects) is the ideal goal of treatment and is often the goal in practice. Synthetic lethality arises when a combination of deficiencies in the expression of two or more genes leads to cell death, whereas a deficiency in only one of these genes does not.

Track 12: Anatomical Pathology

Anatomical pathology is the major specialty of pathology that deals with the study of the morphologic aspects of disease. Anatomical Pathology concerns with the diagnosis of tissue and organ based macro or microscopic testing. The latest research undergoes from the following topics like Radiofrequency identification & specimen tracking, advanced biosafety practices, Multi-model anatomical pathology and Anatomical pathology of sexually transmitted diseases.  There are 36 associations and societies in USA and 18000 pathologists and 90 universities in USA. And 630 companies and 3400 hospitals around USA associated with pathology. The market revenue is expected to reach $74.65 billion by 2020 at a CAGR of 5.34% during 2014-2020. Diagnostic Medicine market growth rate is 5-7% yearly.

Track 13: Cancer Stem Cells and Drug Resistance

Cancer stem cells are cancer cells that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample. CSCs are therefore tumorigenic (tumor-forming), perhaps in contrast to other non-tumorigenic cancer cells. The "mutation in stem cell niche populations during development" hypothesis claims that these developing stem populations are mutated and then reproduce so that the mutation is shared by many descendants. These daughter cells are much closer to becoming tumors and their numbers increase the chance of a cancerous mutation. De-differentiation of mutated cells may create stem cell-like characteristics, suggesting that any cell might become a cancer stem cell.

Track 14: Renal and Urinary tract Pathology

The renal pathology research findings are associated with light microscopy, electron microscopy and immunofluorescence to obtain the accurate diagnosis. Renal Pathology or kidney pathology covers the topics toxic tubular necrosis, renal carcinomas, Diabetic glomerulosclerosis and other kidney related diseases examined under microscope or molecular testing. Renal pathology in nephrology, toxins, tumors and Pathology of lupus glomerulonephritis are also very important research topics for renal pathology. Medical renal diseases may affect the glomerulus, the tubules and interstitium, the vessels, or a combination of these compartments.

Track 15: Oral and Maxillofacial Pathology

Oral & Maxillofacial Pathology refers to the diseases of the mouth, jaws and related structures such as salivary glands, temporomandibular joints, facial muscles and perioral skin. It is a sub-specialty of both dentistry and Pathology or termed as head and neck pathology. It deals with the diagnosis and epidemiology of the disease. It Comprises of Microscopic diagnosis of biopsy specimens, Oral and Maxillofacial surgery, Oral cancers, lesions and surgery in pediatric patients and reconstruction of maxillofacial defects. There are 36 associations and societies in USA and 18000 pathologists and 90 universities in USA. 1400 hospitals around USA associated with pathology.

Track 16: Hematopathology            

Hematopathology is a subspecialty of pathology. Hematopathology concern with the study of hematopoietic cells diseases and hematological disorders. A wide range of diagnosis test are done in Acute and chronic leukemia, Myelodysplastic syndromes, Myeloproliferative disorders, Anemias, Benign bone marrow and lymph node disorders, B-cell lymphomas and T-cell lymphomas and Cutaneous lymphomas. There are 89 universities all over the USA where pathology research works are carried out in that main universities engaged in Hematopathology research are the university of Texas MD Anderson cancer center, Stanford university of Medicine, Yale University and Washington University. National institute of cancer have released $540,054 for Hematopathology research.

Track 17: Pulmonary Pathology

Any abnormal condition of the respiratory system, characterized by cough, chest pain, dyspnea, hemoptysis, sputum production, stridor, or adventitious sounds. Less common symptoms include anxiety, arm and shoulder pain, tenderness in the calf of the leg, erythema nodosum, swelling of the face, headache, hoarseness, joint pain, and somnolence. Diagnostic procedures for pulmonary diseases include bronchoscopy; cytological, serological, and biochemical examination of bronchial secretions; laryngoscopy; pulmonary function tests; and radiography.

Track 18: Microbial Pathology

A pathogen is a microorganism that is able to cause disease in a plant, animal or insect. Pathogenicity is the ability to produce disease in a host organism. Microbes express their pathogenicity by means of their virulence, a term which refers to the degree of pathogenicity of the microbe. Hence, the determinants of virulence of a pathogen are any of its genetic or biochemical or structural features that enable it to produce disease in a host.

Track 19: Gastrointestinal and Liver pathology

Gastrointestinal pathology (including liver, gallbladder and pancreas) is a recognized sub-specialty discipline of surgical pathology. Recognition of a sub-specialty is generally related to dedicated fellowship training offered within the subspecialty or, alternatively, to surgical pathologists with a special interest and extensive experience in gastrointestinal pathology. The gastrointestinal (GI) pathology determines quality diagnostic histopathology on gastrointestinal endoscopic biopsies and resections of the gastrointestinal and pancreatico-biliary systems. Liver disease can occur through several mechanisms. A common form of liver disease is viral infection. Viral hepatitides such as Hepatitis B virus and Hepatitis C virus can be vertically transmitted during birth via contact with infected blood.

Track 20: Dermatopathology

Dermatopathology is a joint subspecialty of dermatology and pathology and to a lesser extent of surgical pathology that focuses on the study of cutaneous diseases at a microscopic and molecular level. It also encompasses analyses of the potential causes of skin diseases at a basic level. In fact, most of them are trained primarily in dermatology themselves. Dermatologists are able to recognize most skin diseases based on their appearances, anatomic distributions, and behavior. Sometimes, however, those criteria do not allow a conclusive diagnosis to be made, and a skin biopsy is taken to be examined under the microscope or subject to other molecular tests. That process reveals the histology of the disease and results in a specific diagnostic interpretation. In some cases, additional specialized testing needs to be performed on biopsies, including immunofluorescence, immunohistochemistry, electron microscopy, flow cytometry, and molecular-pathologic analysis.

Track 21: Digital Pathology and e-Pathology

e-Pathology is defining the new paradigm of anatomic pathology. Telepathology image based information sent to the far distance by telecommunication technology for research analysis in both academic and business side. e-Pathology is a complete scan of a microscopic glass slide and the viewing of the eSlide on a computer monitor through a digital software system. The researches in pathology look beyond the Advancements in diagnosis pathology by using the automated image analysis. The global digital pathology market, valued at $1.98 billion in 2012, is estimated to reach $5.7 billion by 2020. The Association of Digital Pathology is the main Association in Digital pathology field and conducts annual Pathology meetings. Ventana, Leica, Philips, GE Helath care are the main competitors for Digital Pathology software updates and new releases.

Track 22: Veterinary Pathology

Veterinary Pathology is the study and diagnosis of animal disease by using animal tissue and fluids. Veterinary Pathology is classified into two main disciplines; those are veterinary anatomical pathology and veterinary clinical pathology. Veterinary Pathology deals with the following diseases like Veterinary parasite diseases and Veterinary parasitology whereas Veterinary clinical pathology deals with the diagnosis of disease based on the laboratory analysis. The American college of veterinary pathologists and European college veterinary pathologists are the main organizations working on pathology research and grants for the research. Veterinary pathology provides a critical link between the basic and clinical sciences. There are 10 main associations and societies in USA and approximately 60 universities around USA are associated with Veterinary Pathology.

Track 23: Common Cancer Types

The major types of cancer are carcinoma, sarcoma, melanoma, lymphoma, and leukemia. Carcinomas -- the most commonly diagnosed cancers -- originate in the skin, lungs, breasts, pancreas, and other organs and glands. The most common cancer types are Bladder cancer, Colon and Rectal Cancer, Melanoma, Non-Hodgkin Lymphoma, Endometrial Cancer, Kidney Cancer, Leukemia, Thyroid Cancer and Liver cancer.

Market Analysis

Market Analysis of Pathology

The global digital pathology market, valued at $1.98 billion in 2012, is estimated to reach $5.7 billion by 2020. The In vitro diagnostics market revenue is expected to reach $74.65 billion by 2020, from the market value of $53.32 billion in 2013, at a CAGR of 5.34% during 2014-2020. Diagnostic Medicine has $35 billion market, growth 5-7% yearly. Pathology labs will take approximately $15-16 billion in revenue, and they will spend roughly 12% of their revenues with their suppliers all over USA.

Overall Statistics

  • Over 7000 licenses have been issued to pathology labs in the US
  1. 1,600-1,700 commercial labs
  2.  3,300-3,400 hospital labs
  3. 1,800-1,900 physicians’ office labs
  • Academic department in U.S. (130 medical schools; 155 training programs)
  • 59 Universities are there in USA
  • 36 Societies and Association

Market analysis of Cancer:

Cancer Market Study:

Global Oncology/Cancer Drugs Market is expected to garner $111.9 billion by 2020, registering a CAGR of 7.1% during the forecast period 2014 to 2020. Recent progress in biological therapies has widened the scale of therapeutic targets for treatment of cancer with the identification of tumor cell specific genes. Immunotherapies/ biologics are emerging as potential therapies to find the permanent cure for various cancer types. Amongst various biologics, drugs based on monoclonal antibodies (mAbs) have gained significant attention in recent years due to their high efficacy.

Global cancer drugs market accounted for $78,238.9 million in 2015. The cancer drugs market is driven by the growing prevalence of various types of cancer, increasing demand of biological and targeted drug therapies, continuous patent expiry of key cancer drugs and the rising impact of biosimilars. However, the high cost of drug development, the threat of failure and the adverse effects of cancer drug therapy, particularly chemotherapy, hinders the market growth. Developed nations have implemented strict regulations for the design and development of cancer drugs. USFDA and European Union have undertaken significant initiatives to fuel the growth of the cancer drugs market by providing pre-market approval for potential drugs under clinical development. Asia-Pacific and LAMEA are promising regions for conducting clinical trials due a large population base and the low cost of clinical trials as compared to North America and Europe. Nevertheless, advancement of cancer drug research owing to biological/targeted therapies and personalized medicines hold promising opportunities for pharmaceutical, bio-pharmaceutical and biotechnology companies engaged in developing cancer drugs.

Past Conference Report

Pathology 2017

Pathology 2017 Report

We gratefully thank all our wonderful speakers, conference attendees, students, associations and exhibitors for making Pathology 2017 Conference the best ever!

In 2017, the conference took a new direction, broadening its focus beyond the laboratories to cover all aspects of Pathology. This has provided a unique opportunity for academic and Laboratory-wide communication and collaboration and has positioned the conference as annual conference series clinical premier event.

The 13th International Conference on Pathology, hosted by the Conference Series, LLC was held during June 26-27, 2017 at Hilton San Diego Mission Valley, San Diego, California USA, based on the theme “Shaping the Future for Innovations in Pathology and molecular diagnosis". Conference series will acknowledge with gratitude the support by all the Editorial Board Members of Journal of Clinical & Experimental Pathology and Journal of Molecular Diagnostics for their valuable suggestions for up growth of the Organization

The conference was initiated with the Honorable presence of the Keynote forum. The list includes:

  • Shahla Masood, University of Florida, USA
  • Dale D Tang, Albany Medical College, USA
  • Robert H Schiestl, University of California, USA

The meeting reflected various sessions, in which discussions were held on the following major scientific tracks:

  • Anatomical Pathology
  • Clinical Pathology
  • Dermatopathology
  • Renal Pathology
  • Oral and Maxillofacial Pathology
  • Forensic Pathology
  • Veterinary Pathology
  • e-Pathology
  • Molecular Pathology
  • Surgical Pathology                                                         

Conference Series, LLC offers its heartfelt appreciation to the Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who supported the conference by facilitating the discussion forums. Conference Series, LLC also took privilege to felicitate the Organizing Committee Members, Editorial Board Members and Media Partners who supported this event.

With the grand success of Pathology 2017, Conference Series, LLC is proud to announce the "14th International Conference on Pathology" to be held during April 23-24, 2018 at Orlando, USA. Pathology 2018 has been prepared with the aim and the specific intent of promoting the development of new perspectives and ideas for exploiting the high level of knowledge achieved by the scientific community in pathology disciplines.

For More details visit: http://pathology.conferenceseries.com/


Past Reports  Proceedings  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date June 25-26, 2018

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Supported By

Journal of Clinical & Experimental Pathology Journal of Cancer Science & Therapy Journal of Cytology & Histology

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by